1
|
Stellato M, Buti S, Maruzzo M, Bassanelli M, Bersanelli M, Napoli MD, Dionese M, Fanelli M, Filippi R, Fotia G, Galli L, Grillone F, Maffezzoli M, Maiorano BA, Nasso C, Rebuzzi SE, Lalli L, Roviello G, Sorarù M, Vincenzi B, Procopio G, Verzoni E. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27. Clin Genitourin Cancer 2024; 22:102078. [PMID: 38631104 DOI: 10.1016/j.clgc.2024.102078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 03/13/2024] [Accepted: 03/15/2024] [Indexed: 04/19/2024]
Abstract
BACKGROUND Peritoneal metastases (PM) have been reported in approximately 1% of patients with metastatic Renal Cell Carcinoma (mRCC). Outcome data are limited due to the rarity of this metastatic site. Therefore, the aim of our study is to describe renal cell carcinoma (RCC) patients with PM treated as per clinical practice. MATERIALS AND METHODS Baseline characteristics and outcome data of patients with PM from RCC were retrospectively collected from 18 Italian oncological referral centers adhering to the Meet-Uro group, from January 2016 to January 2023. RESULTS We collect 81 RCC patients with PM. 78/81 received systemic treatment, 3/81 only best supportive care. First line treatment included tyrosine-kinase inhibitors (TKI) (46/78), ImmuneOncology (IO)-TKI (26/78) and IO-IO (6/78), with different Objective Response Rate (ORR) (43.4% in TKI monotherapy group vs 50% in IO-TKI group, respectively) and Disease Control Rate (DCR) (60.8% in TKI treated patients vs. 76.9% in IO-TKI treated patients). Median PFS was 6.4 months (95%CI 4.18-14.8) in patients treated with TKI monotherapy vs 23.7 months (95%CI 11.1-NR) in patients treated with IO-TKI (p < 0.015). The median OS (mOS) was 22.7 months (95%CI 13.32 - 64.7) in the TKI monotherapy group vs 34.5 mo (95%CI NR-NR) in the IO-TKI group with 53.8% of patients alive at 1 years in the latter group, (p < 0.16). Primary refractory patients were 36.9% for TKI and 15.3% for IO-TKI. According to International Metastatic renal cell carcinoma Database Consortium (IMDC) score, mPFS and mOS were consistent among risk categories. Median PFS was 36.6 months (95%CI 10.9-NR) for good risk patients compared to 10 months (95%CI 7.5-29.8) for intermediate risk and 2.96 months (95%CI 2.43-11.28) for poor risk population (p < 0.0005) whereas mOS was NR (95%CI 28.65-NR) for good risk patients compared to 35.3 months (95%CI 24.6-NA) and 12.4 months (95%CI 3.52-NR) for intermediate and poor risk population, respectively, (p < 0.0002). Only 34/78 (43.5%) received a second line treatment that was TKI (ORR 8.3% and DCR 41.6%) or IO (ORR 18.1% and DCR 40.9%). CONCLUSION We report one of the largest case series regarding PM from RCC. Characteristics of patients suggest a more aggressive behavior of PM from mRCC. Outcome data suggest that TKI-IO as first line treatment, and TKI as second line, confirm their activity for these patients with dismal prognosis.
Collapse
Affiliation(s)
- Marco Stellato
- Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.
| | - Sebastiano Buti
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - Marco Maruzzo
- Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - Maria Bassanelli
- Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | | | - Marilena Di Napoli
- Department of Oncology, Fondazione IRCCS Istituto Nazionale Tumori "G. Pascale", Napoli, Italy
| | - Michele Dionese
- Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - Martina Fanelli
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | | | - Giuseppe Fotia
- Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Luca Galli
- Department of Surgical, Medical and Molecular Pathology and Critical Area Medicine, University of Pisa, Pisa, Italy
| | | | | | - Brigida Anna Maiorano
- Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy
| | - Cecilia Nasso
- Medical Oncology, Ospedale Santa Corona, Pietra Ligure, Italy
| | - Sara Elena Rebuzzi
- Medical Oncology Unit, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy
| | - Luca Lalli
- Unit of Translational Immunology, IRCCS Foundation National Cancer Institute, Milan, Italy
| | - Giandomenico Roviello
- Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
| | - Mariella Sorarù
- Oncology Unit, Camposampiero General Hospital, Padova, Italy
| | - Bruno Vincenzi
- Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy
| | - Giuseppe Procopio
- Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Elena Verzoni
- Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
2
|
Peruzzi V, Torresan S, Cortiula F, Fanelli M, Ermacora P, Girometti R, Cereser L. Unveiling the Potential of Venn Diagrams as a Helpful Tool for Clinical Reasoning: An Illustrative Case-based Discussion. Curr Probl Diagn Radiol 2023; 52:478-481. [PMID: 37438231 DOI: 10.1067/j.cpradiol.2023.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Accepted: 06/28/2023] [Indexed: 07/14/2023]
Abstract
Venn diagrams graphically represent a cognitive approach that can assist in highlighting information shared by different data sets while eliminating nonoverlapping conditions. When applied to clinical reasoning, such an approach helps physicians visually focus on data pertaining to differential diagnoses. We present and discuss a 3-step reasoning pathway derived from a real-life case in which we used Venn diagrams to diagnose drug-related pneumonitis in a 67-year-old man with advanced bladder cancer and nodular lung findings at chest CT. This education paper supports using Venn diagrams in Radiology.
Collapse
Affiliation(s)
- Valeria Peruzzi
- Institute of Radiology, Department of Medicine, University of Udine, University Hospital S. Maria della Misericordia, Udine, Italy
| | - Sara Torresan
- Department of Oncology, University Hospital S. Maria della Misericordia, Udine, Italy; Department of Medicine, University of Udine, Udine, Italy
| | - Francesco Cortiula
- Department of Oncology, University Hospital S. Maria della Misericordia, Udine, Italy; Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands
| | - Martina Fanelli
- Department of Oncology, University Hospital S. Maria della Misericordia, Udine, Italy
| | - Paola Ermacora
- Department of Oncology, University Hospital S. Maria della Misericordia, Udine, Italy
| | - Rossano Girometti
- Institute of Radiology, Department of Medicine, University of Udine, University Hospital S. Maria della Misericordia, Udine, Italy
| | - Lorenzo Cereser
- Institute of Radiology, Department of Medicine, University of Udine, University Hospital S. Maria della Misericordia, Udine, Italy.
| |
Collapse
|
3
|
Stellato M, Buti S, Maruzzo M, Fotia G, Sorarù M, Bassanelli M, Maiorano BA, Grillone F, Galli L, Filippi R, Fanelli M, Dionese M, Maffezzoli M, Vincenzi B, Procopio G, Verzoni E. Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
Abstract
638 Background: Peritoneal metastases (PM) have been reported in approximately 1% of patients (pts) with metastatic Renal Cell Carcinoma (mRCC). Outcome data are limited due to the rarity of this metastatic site. Therefore, the aim of our study is to describe RCC pts with PM treated as per clinical practice. Methods: Baseline characteristics and outcome data of pts with PM from RCC were retrospectively collected from 12 Italian oncological referral centers adhering to the Meet-Uro group, from January 2016 to September 2022. Results: We collect 91 RCC pts with PM. 87/91 pts received systemic treatment, 4/87 only best supportive care. First line treatment included TKI and ImmuneOncology(IO)-TKI with different Objective Response Rate(ORR) (41% vs 53.8%, respectively) and Disease Control Rate (DCR) (57.1% and 80.7%, respectively) as well as median PFS (9.9 mo (95%CI 4.5-15.4) for TKI and not reached (NR) for IO-TKI (69.7% pts were free from progression at a median follow up of 13.8 months). Primary refractory (PR) pts were 35.7% for TKI and 7.7% for IO-TKI. According to IMDC score, mPFS was consistent among risk categories, 36.8 mo (95%CI 9.6-63.9) for good risk pts, 13.8 mo (95%CI 8.8-18.8) for intermediate pts and 2.9 mo (95%CI 2.2-3.7) for poor risk pts. Synchronous PM was associated to shorter mPFS 11.0 (95%CI 3.1-19.0) compared to patients with metacronous involvement as well as ORR (31.3%) and DCR (43.1%) whereas PR was higher (34.7%). Only 43/87 pts (45.7%) received a second line treatment that was TKI ( ORR 30.7%; DCR 61.5%; or IO (ORR 20.6%; DCR 41.3%). mOS was 21.8 mo (12.0-31.5) for TKI and NR for pts treated with IO-TKI (80.8 alive at 1 yrs). According to IMDC score, mOS was NR for good risk pts, 24.6 (95%CI 15.8-33.3) and 3.4 (95%CI 2.4-4.3) for intermediate and poor risk, respectively. Conclusions: We report one of the largest case series regarding PM from RCC. Poor risk patients according to IMDC score, sarcomatoid feature and liver metastasis were more represented in our population, compared to historical control, suggesting a more aggressive behavior of PM mRCC. Outcome data suggest that TKI-IO as first line treatment, compared to TKI monotherapy, and TKI as second line, compared to IO, are more active treatment for these pts with dismal prognosis. Nevertheless, synchronous PM has been reported in 57% of pts with poorer outcome and lower response rate. [Table: see text]
Collapse
Affiliation(s)
- Marco Stellato
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | | | - Giuseppe Fotia
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Mariella Sorarù
- U.O. Oncologia, Ospedale di Camposampiero (PD), Camposampiero (PD), Italy
| | - Maria Bassanelli
- Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Brigida Anna Maiorano
- Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy
| | | | - Luca Galli
- UO Oncologia Medica 2 Universitaria Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - Roberto Filippi
- Medical Oncology 1, Città della Salute e della Scienza di Torino, Turin, Italy; Department of Oncology, Università di Torino, Turin, Italy
| | - Martina Fanelli
- Department of Oncology, University Hospital of Udine, Udine, Italy
| | - Michele Dionese
- Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | | | - Bruno Vincenzi
- Department of Medical Oncology, Fondazione Policlinico Campus Bio-Medico, Rome, Italy
| | - Giuseppe Procopio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, MI, Italy
| | - Elena Verzoni
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| |
Collapse
|
4
|
Grappolini N, Garbarino S, Fanelli M, Scorza A, Marzorati A, Colombo EM, Palillo A, Palamara N, Inversini D, Ietto G, Carcano G. P-089 SPONTAONEUS BOWEL EVISCERATION IN UMBILICAL HERNIA: CASE REPORT. Br J Surg 2022. [DOI: 10.1093/bjs/znac308.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Aim
Spontaneous rupture of sac of hernia is a less common complication and mainly associated to persistent ascites or congenital wall defects. In literature we have few cases of spontaneous bowel eviscerations in umbilical hernias.
Case Report
a 53-year-old male years old man addicted to heroin, cocaine and alcohol, presented to the Emergency Department with evisceration of small bowel through an existing umbilical hernia. The patient was conscious and not complaining pain. He stated a protrusion of small bowel through his umbilical skin caused to sudden coughing after assumption of a dose of heroin.In emergency room showed an ileal loop with sub ischemic features. Blood test revealed an hepatitis C infection. During the urgent laparotomy there wasn't evidence of ascites and was necessary to performed an ileal resection and latero-lateral anastomosis with mechanical suturing machine. The placement of a prosthesis was performed; therefore, direct plastic surgery of the abdominal wall. After surgery with a short stay in ICU of 24 hours, the patient was discharged in POD 5. The postoperative course was regular without wound complications. After four months he was free from recurrence and VAS was 0.
Conclusions
Spontaneous bowel eviscerations in umbilical hernias is associated with refractory ascites in cirrhotic patients or congenital defect. This case is one of few case depicted in literature as spontaneous evisceration of bowel in non cirrhotic patient with umbilical hernia.
Collapse
Affiliation(s)
- N Grappolini
- Emergency and Transplantation Surgery, University of Insubria , Varese , Italy
| | - S Garbarino
- Emergency and Transplantation Surgery , Ospedale di Circolo, Varese , Italy
| | - M Fanelli
- Emergency and Transplantation Surgery , Ospedale di Circolo, Varese , Italy
| | - A Scorza
- Emergency and Transplantation Surgery, University of Insubria , Varese , Italy
| | - A Marzorati
- Emergency and Transplantation Surgery , Ospedale di Circolo, Varese , Italy
| | - E M Colombo
- Emergency and Transplantation Surgery , Ospedale di Circolo, Varese , Italy
| | - A Palillo
- Emergency and Transplantation Surgery, University of Insubria , Varese , Italy
| | - N Palamara
- Emergency and Transplantation Surgery, University of Insubria , Varese , Italy
| | - D Inversini
- Emergency and Transplantation Surgery, University of Insubria , Varese , Italy
| | - G Ietto
- Emergency and Transplantation Surgery, University of Insubria , Varese , Italy
| | - G Carcano
- Emergency and Transplantation Surgery, University of Insubria , Varese , Italy
| |
Collapse
|
5
|
Monti E, Latham L, Gianazza S, Zullo A, Odeh M, Colombo EM, Marzorati A, Fanelli M, Costa J, Inversini D, Ietto G, Carcano G. V-056 LAPAROSCOPIC VENTRAL HERNIA REPAIR WITH GORE SINECOR INTRAPERITONEAL BIOMATERIAL: OUR CENTER EXPERIENCE. Br J Surg 2022. [DOI: 10.1093/bjs/znac308.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Aim
Ventral hernias including incisional ones are very common in our population. Mesh reinforcement options for ventral/incisional hernia repair continue to evolve with advances in polymer science and better understanding of the extracellular matrix. Consensus on the safety and efficacy of these various types of synthetic and biologic mesh has yet to be reached.
Intraperitoneal onlay mesh (IPOM) is the laparoscopic technique most frequently used in our center to treat umbilical and abdominal ventral defects sized 3 cm to 8 cm. Our equipe built an expertise with Gore DualMesh prosthesis (2% recurrence ratio in our center); we used the Gore Sinecor Intraperitoneal Biomaterial for the first time here.
Methods
Symptomatic supraumbilical incisional hernia in a 74 years old man; parietal defect sized 7×8 cm. We performed an Ipom repair procedure using a 20×25 cm Gore Sinecor Intraperitoneal Biomaterial, trimmed to 18×20 cm. Follow-up at one and six months from surgery.
Results
The patient was discharged the day after surgery. He did not complain severe pain in the first week after surgery and he only use Paracetamolo 1g die as antalgic therapy. After seven days he resumed his daily activities.
He did not experience any short-term sieroma nor long-term complication at follow up.
Conclusions
The Gore Sinecor Intraperitoneal Biomaterial, while maintaining a firm peritoneal adhesivity, has a better handling and feels lighter than the Gore DualMesh we routinely use. The transparency makes it possible to visualize the overlying abdominal wall, allowing a safer tacs positioning.
Collapse
Affiliation(s)
- E Monti
- Emergency and Transplantation Surgery, ospedale di Cittiglio , Cittiglio , Italy
| | - L Latham
- Emergency and Transplantation Surgery, Ospedale di Circolo , Varese , Italy
| | - S Gianazza
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - A Zullo
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - M Odeh
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - E M Colombo
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - A Marzorati
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - M Fanelli
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - J Costa
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - D Inversini
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - G Ietto
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| | - G Carcano
- Emergency and Transplantation Surgery, Università dell'Insubria , Varese , Italy
| |
Collapse
|
6
|
Dri A, Garattini SK, Cinausero M, Macerelli M, Fanelli M, Puglisi F, Fasola G, Ermacora P. Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice. Curr Oncol 2022; 29:6776-6786. [PMID: 36290810 PMCID: PMC9600961 DOI: 10.3390/curroncol29100533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 09/11/2022] [Accepted: 09/16/2022] [Indexed: 01/13/2023] Open
Abstract
The advent of immune checkpoint inhibitors in combination with multitarget tyrosine kinase inhibitors has become a standard first-line treatment for metastatic renal cell cancer. Along with survival improvement, new toxicities have emerged. Such adverse events are still complex to be managed and some of them are rare and could be insidious or even fatal. Medical oncologists dispose of guidelines about the management of toxicities from immune checkpoint inhibitors but not for combinations. Therefore, it is still difficult to properly attribute and manage additive or overlapping adverse events. We report two clinical cases regarding rare treatment-related endocrine toxicities-hypophysitis and thyroiditis-with particular focus on their management. To this purpose, immune checkpoint-related toxicities guidelines represent the starting point. However, their implementation with additional measures is needed, considering the increasing complexity of current clinical scenarios. The goal is to correctly recognize adverse events and address side effects, so as not to discontinue effective treatments. We, therefore, aim at discussing the points of proper management of toxicities and individuating potential areas of improvement.
Collapse
Affiliation(s)
- Arianna Dri
- Department of Medicine (DAME), University of Udine, 33100 Udine, Italy
- Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
- Correspondence:
| | - Silvio Ken Garattini
- Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
| | - Marika Cinausero
- Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
| | - Marianna Macerelli
- Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
| | - Martina Fanelli
- Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
| | - Fabio Puglisi
- Department of Medicine (DAME), University of Udine, 33100 Udine, Italy
- Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCSS, 33081 Aviano, Italy
| | - Gianpiero Fasola
- Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
| | - Paola Ermacora
- Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
| |
Collapse
|
7
|
De Biasi S, Guida A, Lo Tartaro D, Fanelli M, Depenni R, Dominici M, Finak G, Porta C, Paolini A, Borella R, Bertoldi C, Cossarizza A, Sabbatini R, Gibellini L. Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy. Cytometry A 2022; 101:597-605. [PMID: 35507402 PMCID: PMC9542732 DOI: 10.1002/cyto.a.24562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 04/19/2022] [Accepted: 04/22/2022] [Indexed: 11/20/2022]
Abstract
Renal‐cell carcinoma (RCC) is responsible for the majority of tumors arising from the kidney parenchyma. Although a progressive improvement in median overall survival has been observed after the introduction of anti‐PD‐1 therapy, many patients do not benefit from this treatment. Therefore, we have investigated T cell dynamics to find immune modification induced by anti‐PD‐1 therapy. Here, we show that, after therapy, RCC patients (5 responders and 14 nonresponders) are characterized by a redistribution of different subsets across the memory T cell compartment.
Collapse
Affiliation(s)
- Sara De Biasi
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna
| | - Annalisa Guida
- Azienda Ospedaliera Santa Maria, Terni, Italy.,Department of Oncology, University of Modena & Reggio Emilia, Modena, Italy
| | - Domenico Lo Tartaro
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Martina Fanelli
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna.,Department of Oncology, University of Modena & Reggio Emilia, Modena, Italy
| | - Roberta Depenni
- Department of Oncology, University of Modena & Reggio Emilia, Modena, Italy
| | - Massimo Dominici
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna.,Department of Oncology, University of Modena & Reggio Emilia, Modena, Italy
| | - Greg Finak
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | | | - Annamaria Paolini
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Rebecca Borella
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Carlo Bertoldi
- Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Italy
| | - Andrea Cossarizza
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna.,National Institute for Cardiovascular Research, Bologna
| | - Roberto Sabbatini
- Department of Oncology, University of Modena & Reggio Emilia, Modena, Italy
| | - Lara Gibellini
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Emilia-Romagna
| |
Collapse
|
8
|
Bersanelli M, Buti S, Rizzo M, Cortellini A, Cattrini C, Massari F, Masini C, Vitale MG, Fornarini G, Caffo O, Atzori F, Gatti A, Macrini S, Mucciarini C, Galli L, Morelli F, Stellato M, Fanelli M, Corti F, Zucali PA, Toscani I, Dalla Volta A, Gernone A, Baldessari C, La Torre L, Zara D, Gennari A, Bracarda S, Procopio G, Porta C. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. Ther Adv Urol 2021; 13:17562872211054302. [PMID: 34707691 PMCID: PMC8543560 DOI: 10.1177/17562872211054302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 09/30/2021] [Indexed: 11/26/2022] Open
Abstract
Background: Considering the growing genitourinary (GU) cancer population undergoing systemic treatment with immune checkpoint inhibitors (ICIs) in the context of the COVID-19 pandemic, we planned a clinical audit in 24 Italian institutions treating GU malignancies. Objective: The primary objective was investigating the clinical impact of COVID-19 in GU cancer patients undergoing ICI-based therapy during the first outbreak of SARS-CoV-2 contagion in Italy. Design, setting, and participants: The included centers were 24 Oncology Departments. Two online forms were completed by the responsible Oncology Consultants, respectively, for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC) patients receiving at least one administration of ICIs between 31 January 2020 and 30 June 2020. Results and limitation: In total, 287 mRCC patients and 130 mUC patients were included. The COVID-19 incidence was, respectively, 3.5%, with mortality 1%, in mRCC patients and 7.7%, with mortality 3.1%, in mUC patients. In both groups, 40% of patients developing COVID-19 permanently discontinued anticancer treatment. The pre-test SARS-CoV-2 probability in the subgroup of patients who underwent nasal/pharyngeal swab ranged from 14% in mRCC to 26% in mUC. The main limitation of the work was its nature of audit: data were not recorded at the single-patient level. Conclusion: GU cancer patients undergoing active treatment with ICIs have meaningful risk factors for developing severe events from COVID-19 and permanent discontinuation of therapy after the infection. Treatment delays due to organizational issues during the pandemic were unlikely to affect the treatment outcome in this population.
Collapse
Affiliation(s)
| | - Sebastiano Buti
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - Mimma Rizzo
- Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy
| | - Alessio Cortellini
- Department of Biotechnology and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - Carlo Cattrini
- Division of Oncology, Maggiore della Carità Hospital, Novara, Italy
| | - Francesco Massari
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Cristina Masini
- Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Emilia, Italy
| | - Maria Giuseppa Vitale
- Department of Oncology and Haematology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
| | - Giuseppe Fornarini
- Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | - Orazio Caffo
- Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
| | - Francesco Atzori
- Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
| | - Alice Gatti
- Division of Oncology, Maggiore della Carità Hospital, Novara, Italy
| | - Serena Macrini
- Department of Oncology, Azienda USL Toscana Sud Est, Arezzo, Italy
| | | | - Luca Galli
- Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy
| | - Franco Morelli
- Medical Oncology Department, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
| | - Marco Stellato
- Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy
| | - Martina Fanelli
- Department of Oncology and Haematology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
| | - Francesca Corti
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Paolo Andrea Zucali
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
- Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy
| | - Ilaria Toscani
- Oncology & Hematology Department, Oncology Unit, Piacenza General Hospital, Piacenza, Italy
| | - Alberto Dalla Volta
- Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Brescia, Italy
| | - Angela Gernone
- Division of Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy
| | - Cinzia Baldessari
- Department of Oncology and Haematology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
| | - Leonardo La Torre
- Medical Oncology Department, Santa Maria della Scaletta Hospital, Imola, Italy
| | - Diego Zara
- Department of Medicine (DAME), University of Udine, Udine, Italy
- Department of Oncology, ASUFC University Hospital of Udine, Udine, Italy
| | - Alessandra Gennari
- Department of Translational Medicine, University of Piemonte Orientale, Vercelli, Italy; Division of Oncology, Maggiore della Carità Hospital, Novara, Italy
| | - Sergio Bracarda
- Department of Oncology, Azienda USL Toscana Sud Est, Arezzo, Italy
| | - Giuseppe Procopio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Camillo Porta
- Division of Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy
- Chair of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Bari, Italy
| |
Collapse
|
9
|
Vitale MG, Nasso C, Oltrecolli M, Baldessari C, Fanelli M, Dominici M, Sabbatini R. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. Expert Rev Anticancer Ther 2021; 21:1183-1192. [PMID: 34424125 DOI: 10.1080/14737140.2021.1971519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION In the last decade, there have been substantial changes in the management of metastatic renal cell carcinoma (mRCC) with combined regimens with immune checkpoint inhibitors (ICI) replacing targeted therapies. These combined regimens include the combination of cabozantinib plus nivolumab. AREAS COVERED Here, we provide an overview of clinical trials evaluating the combination of cabozantinib and nivolumab and the current clinical data on mechanism of action, pharmacokinetics, efficacy, and safety profile. EXPERT OPINION Dual immune checkpoint inhibition with nivolumab and ipilimumab as well as the combination of a vascular endothelial growth factor (VEGF) inhibitor and an immune checkpoint inhibitor have shown to improve outcomes in phase III trials in comparison to sunitinib (axitinib plus pembrolizumab, axitinib plus avelumab, bevacizumab plus atezolizumab, cabozantinib plus nivolumab, lenvatinib plus pembrolizumab). However, to date, there are no head-to-head trials comparing these new combination therapies and no biomarkers are available to guide the optimal choice of first line therapy.
Collapse
Affiliation(s)
| | - Cecilia Nasso
- Department of Oncology and Haematology, Modena University Hospital, Modena, Italy
| | - Marco Oltrecolli
- Department of Oncology and Haematology, Modena University Hospital, Modena, Italy
| | - Cinzia Baldessari
- Department of Oncology and Haematology, Modena University Hospital, Modena, Italy
| | - Martina Fanelli
- Department of Oncology and Haematology, Modena University Hospital, Modena, Italy
| | - Massimo Dominici
- Department of Oncology and Haematology, Modena University Hospital, Modena, Italy
| | - Roberto Sabbatini
- Department of Oncology and Haematology, Modena University Hospital, Modena, Italy
| |
Collapse
|
10
|
Fanelli M, Caputo F, Cerma K, Gelsomino F, Bari A, Dominici M, Pozzi S. Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature. J Oncol Pharm Pract 2020; 27:766-770. [PMID: 32838682 DOI: 10.1177/1078155220950440] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Pazopanib, a tyrosine kinase inhibitor (TKI), is a standard treatment for various tumours, including metastatic non-adipocytic soft-tissue sarcomas. In literature, erythrocytosis has been described as a TKI-related condition. CASE REPORT A 59-year-old man underwent surgical removal of a sub-scapular mass consistent with myxofibrosarcoma. After distant relapse, he first started chemotherapy, and then Pazopanib. He was found to have increased levels of hemoglobin (Hb) and hematocrit (Hct). He was asymphtomatic, with no history of pulmonary disease nor smoking habit. Erythropoietin (EPO) level was higher than normal. A polycythemia vera was ruled out.Management & outcome: The patient started a prophylactic therapy with lysine acetylsalicylate, and we observed a reduction of Hb, but not Hct. Due to disease progression, we interrupted Pazopanib. After a week from drug discontinuation, Hb levels got back to the normal range, Hct was lowering. We decided not to perform phlebotomy, considering the declining trend in Hb and Hct values and the absence of symptoms. DISCUSSION We postulated a Pazopanib-related secondary erythrocytosis, since Hb and Hct levels increased from baseline during treatment, then normalized when Pazopanib was discontinued. We used the Naranjo Nomogram to assess the correlation between the adverse effect and Pazopanib, the correlation was "Probable", a score of 5. To the best of our knowledge, this is the first case report of Pazopanib-related secondary polycythemia in a patient with sarcoma. It is important to pay attention to blood count and to any symptoms potentially related to erythrocytosis in patients treated with TKIs.
Collapse
Affiliation(s)
- Martina Fanelli
- Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
| | - Francesco Caputo
- Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
| | - Krisida Cerma
- Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
| | - Fabio Gelsomino
- Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
| | - Alessia Bari
- Unit of Target Therapy in Onco-Hematology and Osteoncology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
| | - Massimo Dominici
- Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
| | - Samantha Pozzi
- Unit of Target Therapy in Onco-Hematology and Osteoncology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
11
|
Lavelli V, Nappi AG, Caputo P, Asabella AN, Fanelli M, Sardaro A, Altini C, Ferrari C, Rubini G. Impact of pre-treatment variables on the completion of 223radium-dichloride therapy in mCRPC patients with bone metastases. Hell J Nucl Med 2019; 22 Suppl 2:153-163. [PMID: 31802056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Accepted: 11/11/2019] [Indexed: 06/10/2023]
Abstract
INTRODUCTION Radium-223 dichloride (223Ra) is an alpha-particle-emitter radiopharmaceutical, approved for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral involvement. Its administration is based on a schedule of intravenous injection (55kBq/kg) every four weeks for up to six cycles. Because the biological effectiveness of 223Ra-therapy is dose-dependent, the main goal is to complete the entire treatment to achieve a better patient outcome. This study aims to identify potential pre-treatment variables that could impact on 223Ra-treatment completion and then be used to improve the clinical and supportive management of mCRPC patients. MATERIALS AND METHODS 30 consecutive mCRPC patients (mean age 77 years old), who were admitted for Ra223-therapy at our Department from February 2016 to October 2018, were enrolled for the analysis. The population was grouped as patients who completed 223Ra-therapy (group Ra223-C) and patients who do not (group 223Ra-U). For each group, we analyzed the effects of potential pre-treatment variables (age, Gleason Score, tumor burden, "Time From Diagnosis To 223Ra therapy", type and number of previous treatments, hemoglobin level, Alkaline Phosphatase, Prostate Specific Antigen and pain) on the Ra223-therapy completion. Statistical analysis was performed to evaluate the association between the completion of 223Ra therapy and the variables examined. RESULTS 16/30 (53%) patients were 223Ra-C, conversely 14/30 (47%) patients were 223Ra-U because of an early interrupted treatment. A statistically significant association was found only with tumor burden: 68.7% of patients who completed 223-therapy had less than 20 bone metastases (χ2=4.821, p=0.028). CONCLUSION Our preliminary analysis demonstrates that the high tumor burden represents the most important pre-treatment factor that could affect treatment completion and that needs to be considered before starting 223Ra-therapy to achieve a better outcome in mCRPC patients.
Collapse
Affiliation(s)
- V Lavelli
- Nuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Piazza Giulio Cesare, 11, 70124, Bari, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Morabito A, Bevilacqua P, Vitale S, Fanelli M, Gattuso D, Gasparini G. Clinical Management of a Case of Recurrent Apocrine Gland Carcinoma of the Scalp: Efficacy of a Chemotherapy Schedule with Methotrexate and Bleomycin. Tumori 2018; 86:472-4. [PMID: 11218189 DOI: 10.1177/030089160008600608] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Apocrine carcinoma of the skin is a rare tumor. Wide surgical excision with complete removal of the neoplasm is the standard therapy and this appears to offer the best chance of cure. Radiotherapy may be used in case of local relapse or regional lymph node involvement. Systemic chemotherapy has not proved to be effective in the treatment of this tumor. We report on a 46-year-old woman with a recurrent apocrine carcinoma of the scalp that had previously been treated with surgery, radiotherapy and chemotherapy (Al-Saraff schedule). The patient was responsive to a second-line systemic chemotherapy regimen consisting of a weekly combination of methotrexate and bleomycin, and achieved long-term progression-free survival.
Collapse
Affiliation(s)
- A Morabito
- Division of Medical Oncology, Azienda Ospedaliera Bianchi-Melacrino Morelli, Reggio Calabria, Italy
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
Growth of solid tumors beyond a certain mass is dependent on the vascular bed from pre-existing host vasculature. The process of angiogenesis is essential not only for primary tumor growth but also for metastasis. The number of microvessels within the invasive component of a primary tumor reflects the degree of tumor angiogenesis. At present the most widely used method to assess neovascularization is the quantitation of intratumoral microvessel density (IMD) by immunohistochemical methods in which specific markers for endothelial cells are employed. In this paper we analyze the different methods used to assess IMD, as well as their advantages and potential methodological pitfalls. Several studies have shown a close correlation between IMD, tumor growth and the occurrence of metastasis, suggesting that IMD is a prognostic indicator of clinical relevance. Furthermore, preliminary studies suggest that determination of angiogenesis may predict responsiveness to some forms of conventional anticancer therapy. Although the histological microvessel density technique is the current gold standard to characterize tumor angiogenesis, it may not be the ideal tool for clinical purposes because it needs to be performed on biopsy material and does not assess the functional pathways involved in the angiogenic activity of tumors. Non-invasive assessment of tumor vascularity is possible in vivo by means of Doppler sonography, dynamic contrast-enhanced magnetic resonance imaging (MRI) and positron emission tomography (PET). These methods may be preferable to histological assay because they are non-invasive, survey the entire tumor, reflect both anatomic and physiologic characteristics, and may be useful to monitor the activity of antiangiogenic therapies.
Collapse
Affiliation(s)
- M Fanelli
- Division of Medical Oncology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
| | | | | | | |
Collapse
|
14
|
Abstract
PURPOSE Open fractures are considered an orthopaedic emergency and are generally an indication for operative debridement. Recent studies have questioned this approach for the management of Gustilo-Anderson Type I open fractures in the paediatric population. This meta-analysis studies the non-operative management of Type I open paediatric forearm fractures. METHODS An Ovid MEDLINE and PubMed database literature search was performed for studies that involved a quantified number of Gustilo-Anderson Type I open forearm fractures in the paediatric population, which were treated without operative intervention. A fixed-effect meta-analysis, weighting each study based on the number of patients, and a pooled estimate of infection risk (with 95% confidence interval (CI)) was performed. RESULTS The search results yielded five studies that were eligible for inclusion. No included patients had operative debridement and all were treated with antibiotics. The number of patients in each study ranged from 3 to 45, with a total of 127 paediatric patients in the meta-analysis. The infection rate was 0% for all patients included. The meta-analysis estimated a pooled infection risk of 0% (95% CI 0 to 2.9). CONCLUSIONS The five included studies had a total of 127 patients with no cases of infection after non-operative management of Type I open paediatric forearm fractures. The infection rate of Type I fractures among operatively managed patients is 1.9%. The trend in literature towards non-operative treatment of paediatric Type I open fractures holds true in this meta-analysis.
Collapse
Affiliation(s)
- H. Zhang
- Geisinger Health System, Department of Orthopaedics, Danville, PA 17822, USA,Correspondence should be sent to: Hui Zhang, Geisinger Health System, Department of Orthopaedics, Danville, PA 17822, USA. E-mail:
| | - M. Fanelli
- Geisinger Health System, Department of Orthopaedics, Danville, PA 17822, USA
| | - C. Adams
- University of Vermont College of Medicine, Burlington, VT 05405, USA
| | - J. Graham
- Geisinger Health System, Department of Orthopaedics, Danville, PA 17822, USA
| | - M. Seeley
- Geisinger Health System, Department of Orthopaedics, Danville, PA 17822, USA
| |
Collapse
|
15
|
Buondonno I, Gazzano E, Sea Rin J, Audrito V, Kopecka J, Fanelli M, Salaroglio I, Costamagna C, Roato I, Mungo E, Hattinger C, Deaglio S, Kelley S, Serra M, Riganti C. Mitochondria-targeted doxorubicin: A new therapeutic strategy against drug-resistant osteosarcoma. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32801-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Martellucci I, Fanelli M, Cherri S, Multari A, Pesola G, Rosellini P, Ciompi A, Francini G. Pre-graduate internship in the medical oncology department: a good training setting to capture aspects of palliative and simultaneous care. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw336.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Foti C, Fanelli M, Mastrandrea V, Buquicchio R, Cassano N, Conserva A, Nettis E. Risk Factors for Sensitization to Anisakis Simplex: A Multivariate Statistical Evaluation. Int J Immunopathol Pharmacol 2016; 19:847-51. [PMID: 17166406 DOI: 10.1177/039463200601900414] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Anisakis simplex is a nematode belonging to the Anisakidae family. The ingestion of third stage larvae in uncooked or undercooked seafood may cause human diseases known as anisakiasis and anisakidosis. A total of 400 (159 atopic and 241 non-atopic) subjects living in an area of southern Italy (Bari district) were consecutively evaluated to identify the association of some factors (sex, age, atopy, consumption of uncooked seafood and sensitization to dust mites) with the risk of Anisakis simplex sensitization. Patients were investigated on history of atopy and allergic diseases and were skin prick tested with commercial allergen extracts of Anisakis simplex, Acarus siro, Lepidoglyphus destructor, Tyrophagus putrescentiae, Glycyphagus domesticus, Euroglyphus maynei, Dermatophagoides pteronyssinus and Dermatophagoides faunae. Our results suggest that atopic subjects have a lower risk of Anisakis allergy than non-atopic subjects and show the association of Anisakis simplex sensitization with the consumption of uncooked seafood (anchovies and squid), increasing age and sensitization to Glycyphagus domesticus.
Collapse
Affiliation(s)
- C Foti
- Department of Internal Medicine, Immunology and Infectious Diseases, Section of Dermatology University of Bari, Policlinico, Bari, Italy.
| | | | | | | | | | | | | |
Collapse
|
18
|
Ranieri G, Marech I, Altini C, Fazio V, Caporusso L, Porcelli M, Vinciarelli G, Macina F, de Ceglia D, Fanelli M, Ammendola M, Armenise F, Niccoli Asabella A, Rubini G, Gadaleta C. A phase II study employing Hepatic Intrarterial Irinotecan Drug-Eluiting Beads (DEBIRI) as salvatage therapy in liver metastatic colorectal cancer patients: the first South Italy experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Ferreira R, Gonzaga A, Cardoso P, Santos J, Stanislao M, Facciorusso A, Di Stolfo G, Criconia G, Parisi A, Michelini S, Fanelli M, Valle G, Gokhan O, Hasan A, Mehmet D, Mehmet M, Selvi C, Mustafa K, Ismet Z, Din S, Snowdon R, Williams K, Michail M, Koh T. Clinical Case Session I: Sunday 3 May 2015, 10:00-11:00 * Room: Venecia. Eur Heart J Cardiovasc Imaging 2015. [DOI: 10.1093/ehjci/jev044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Poloni A, Maurizi G, Mattiucci D, Amatori S, Fogliardi B, Costantini B, Mariani M, Mancini S, Olivieri A, Fanelli M, Leoni P. Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes. Leukemia 2014; 28:2241-4. [DOI: 10.1038/leu.2014.197] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
Ceretti M, Fanelli M, Pappalardo S. Aseptic, simultaneous and bilateral mobilization due to an acetabular shell fracture in a 43 year-old patient. Rev Esp Cir Ortop Traumatol (Engl Ed) 2014. [DOI: 10.1016/j.recote.2014.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
22
|
Ceretti M, Fanelli M, Pappalardo S. [Aseptic, simultaneous and bilateral mobilisation due to an acetabular shell fracture in a 43 year-old patient]. Rev Esp Cir Ortop Traumatol (Engl Ed) 2013; 58:57-9. [PMID: 24360788 DOI: 10.1016/j.recot.2013.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Accepted: 07/25/2013] [Indexed: 11/18/2022] Open
Abstract
The acetabular shell mobilization is the main long-term complication in total hip replacement. Metal-back fracture has also to be considered among the possible causes of shell mobilization. A case is presented of bilateral acetabular shell mobilization due to the trabecular covering de-soldering from the metal-back in a 43 year-old patient, 13-14 years after the first surgery.
Collapse
Affiliation(s)
- M Ceretti
- Department of Orthopaedic Surgery, «Sapienza» University of Rome, Rome, Italy.
| | - M Fanelli
- Department of Orthopaedic Surgery, «Sapienza» University of Rome, Rome, Italy
| | - S Pappalardo
- Department of Orthopaedic Surgery, «Sapienza» University of Rome, Rome, Italy
| |
Collapse
|
23
|
Gomez H, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, Santi PX, Pinczowsky H, Neron Y, Fanelli M, Fein L, Sampaio C, Lerzo G, Capo A, Zarba JJ, Blajman C, Varela MS, Martínez-Mesa J, Werutsky G, Barrios CH. Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Lapatinib-Capecitabine (LC) is approved for the treatment of advanced or metastatic breast cancer (MBC) whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane (T), and trastuzumab (H). LACOG 0801 evaluated different L-based chemotherapies as first and second-line treatments in MBC.
Methods:
This is a randomized, open label, multicenter, phase II trial of L 1250 mg BID given continuously in combination with C 2000 mg/m2 d1-14 (LC), or Vinorelbine (V) 25mg/m2 d1 and 8 (LV) or Gemcitabine (G) 1000 mg/m2 d1 and 8 (LG), in 21 days cycles. Primary endpoint was ORR (RECIST). Secondary endpoints included progression free survival (PFS), overall survival, tolerability and safety. Patients with HER2 positive MBC who had failed a T-based treatment and who had ≤1 chemotherapy regimen in the metastatic setting were included. Prior therapy with H was not mandatory. Patients were stratified by the presence of liver metastasis, previous use of H, and T administered in the neo/adjuvant or the metastatic setting. With an expected ORR of 23% in the control arm (LC), we hypothesized an absolute increase of 12% in the experimental arms using Simon's design.
Results:
A total of 142 pts from Argentina, Brazil and Peru were included from 2009-2012. Patient baseline characteristics were well balanced between the three arms. Median age was 51y, 58% postmenopausal, 65% ECOG 1, 49% had visceral disease (32% liver metastasis), 57% hormone receptor negative and only 47% had received prior H. Median number of administered cycles was 6 (LC = 5; LV = 7; LG = 6). ORR was 47.1% (95%CI 38.5; 67.1), 55.6% (95%CI 29.6; 60.0) and 41.3% (95%CI 43.2; 73.0) in LC, LV and LG, respectively. Median PFS was 9.1m (95%CI 6.1; 14.7), 7.0m (95%CI 5.0; 9.9) and 6.8m (95%CI 5.8; 9.9) in LC, LV and LG arms respectively. Survival data will be updated. The proportion of patients with at least one adverse event (AE) was 96% in all arms. Most common all grade AE were diarrhea (76%), hand-foot syndrome (HFS) (45%) and vomiting (39%) in LC; diarrhea (71%), neutropenia (68%) and nausea (43%) in LV; diarrhea (64%), neutropenia (60%), anemia and increased ALT both 44% in LG. The most frequent grade 3 and 4 AEs were HFS (18%), diarrhea (6%) and increased ALT/AST (4%) in LC; neutropenia (36%), diarrhea (9%) and febrile neutropenia (6%) in LV; and neutropenia (47%), ALT/AST elevation (13%) and rash (4%) in LG. Discontinuation due to toxicity occurred in 16%, 7% and 20% of patients in arms LC, LV and LG respectively.
Conclusion:
LV and LG seems to be active combinations in patients with HER2 positive MBC after T failure. The high ORR observed in this study might be explained, among other factors, by the inclusion of patients with less prior treatment exposure. No new safety signals where reported with these two novel Lapatinib/chemotherapy combinations. The different side effect profile may help in selecting the most appropriate regimen for a particular patient.
Sponsor: Latin American Cooperative Oncology Group (LACOG) with support from GlaxoSmithKline.
ClinicalTrials.gov number NCT01050322.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-26.
Collapse
Affiliation(s)
- H Gomez
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - S Neciosup
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - C Tosello
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - M Mano
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - J Bines
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - G Ismael
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - PX Santi
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - H Pinczowsky
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - Y Neron
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - M Fanelli
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - L Fein
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - C Sampaio
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - G Lerzo
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - A Capo
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - JJ Zarba
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - C Blajman
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - MS Varela
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - J Martínez-Mesa
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - G Werutsky
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| | - CH Barrios
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Instituto Nacional de Câncer do Brasil, Rio de Janeiro, Brazil; Fundação Doutor Amaral Carvalho, Jaú, Brazil; Faculdade de Medicina do ABC, Santo André, Brazil; Centro de Pesquisas Oncológicas de Santa Catarina, Florianópolis, Brazil; Hospital A.C. Camargo, São Paulo, Brazil; Centro Oncológico de Rosário, Rosario, Argentina; Clinica Amo, Salvador, Brazil; Investigaciones Clinicas Ciudad de Buenos Aires, Buenos Aires, Argentina; Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina; Centro San Roque, Tucuman, Argentina; ISIS Clínica Especializada, Santa Fé, Argentina; CER Instituto Médico, Buenos Aires, Argentina; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; PUCRS School of Medicine, Hospital São Lucas, Porto Alegre, Brazil
| |
Collapse
|
24
|
Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, Landuzzi L, Magagnoli G, Versteeg R, Picci P, Hattinger CM, Serra M. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer 2013; 109:2607-18. [PMID: 24129234 PMCID: PMC3833226 DOI: 10.1038/bjc.2013.643] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2013] [Revised: 09/20/2013] [Accepted: 09/24/2013] [Indexed: 12/19/2022] Open
Abstract
Background: Aurora kinases are key regulators of cell cycle and represent new promising therapeutic targets in several human tumours. Methods: Biological relevance of Aurora kinase-A and -B was assessed on osteosarcoma clinical samples and by silencing these genes with specific siRNA in three human osteosarcoma cell lines. In vitro efficacy of two Aurora kinases-targeting drugs (VX-680 and ZM447439) was evaluated on a panel of four drug-sensitive and six drug-resistant human osteosarcoma cell lines. Results: Human osteosarcoma cell lines proved to be highly sensitive to both drugs. A decreased drug sensitivity was observed in doxorubicin-resistant cell lines, most probably related to ABCB1/MDR1 overexpression. Both drugs variably induced hyperploidy and apoptosis in the majority of cell lines. VX-680 also reduced in vitro cell motility and soft-agar cloning efficiency. Drug association experiments showed that VX-680 positively interacts with all conventional drugs used in osteosarcoma chemotherapy, overcoming the cross-resistance observed in the single-drug treatments. Conclusion: Aurora kinase-A and -B represent new candidate therapeutic targets for osteosarcoma. In vitro analysis of the Aurora kinases inhibitors VX-680 and ZM447439 indicated in VX-680 a new promising drug of potential clinical usefulness in association with conventional osteosarcoma chemotherapeutic agents.
Collapse
Affiliation(s)
- E Tavanti
- Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Via di Barbiano 1/10, I-40136 Bologna, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ambrogini P, Lattanzi D, Ciuffoli S, Betti M, Fanelli M, Cuppini R. Physical exercise and environment exploration affect synaptogenesis in adult-generated neurons in the rat dentate gyrus: possible role of BDNF. Brain Res 2013; 1534:1-12. [PMID: 23973748 DOI: 10.1016/j.brainres.2013.08.023] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Revised: 08/06/2013] [Accepted: 08/12/2013] [Indexed: 01/02/2023]
Abstract
A brief training in a pool maze, with or without cognitive tasks, modifies the synaptogenesis and maturation of newborn neurons in adult rat dentate gyrus. These types of trainings have many aspects, including physical activity and exploration. Therefore, to evaluate whether physical exercise and environment exploration are able to affect synapse formation and the maturation of adult-generated neurons, GFP-retrovirus infusion was performed on rats which, on the fourth day after injection, were housed under running conditions or allowed to explore an enriched environment briefly in the absence of exercise for the following three days. Afterward, at the end of the trainings, electrophysiological and morphological studies were conducted. Considering that neurotrophic factors increase after exercise or environment exploration, hippocampal BDNF levels and TrkB receptor activation were evaluated. In this study, we show that both spontaneous physical activity and enriched environment exploration induced synaptogenesis and T-type voltage-dependent Ca(2+) currents in very immature neurons. Hippocampal BDNF levels and TrkB receptor activation were determined to be increasing following physical activity and exploration. A possible contribution of BDNF signaling in mediating the observed effects was supported by the use of 7-8-dihydroxyflavone, a selective TrkB agonist, and of ANA-12, an inhibitor of TrkB receptors.
Collapse
Affiliation(s)
- P Ambrogini
- Department of Earth, Life and Environment Sciences, Section of Physiology, University of Urbino "Carlo Bo", Urbino 61029, Italy.
| | | | | | | | | | | |
Collapse
|
26
|
Theodorakis E, Fanelli M, Ottolenghi P, Pappalardo S. An unconventional indication of the Sauve' - Kapandji procedure in a radial shaft pseudoarthrosis and chronic DRUJ dislocation: a case report. Clin Ter 2013; 164:e133-6. [PMID: 23698215 DOI: 10.7417/ct.2013.1545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We present a 42-years-old male who developed a radial shaft pseudoartrosis and a chronic DRUJ dislocation/instability, following a Galeazzi fracture. He presented to our Office with a severe inability of wrist and forearm motion. A Sauve'-Kapandji procedure was adopted, performing a lateral approach to the ulna and grafting the excised ulnar block to retrieve radial length at the pseudoarthrosis level. Cancellous bone grafts from the iliac crest were also applied and mixed with autologous platelet rich plasma to promote callus formation. The goal was to create an intentional pseudoarthrosis of the distal ulna combined with a DRUJ arthrodesis, in order to resolve instability and regain forearm pronation/supination. We obtained bone healing, an excellent clinical recovery, and the patient returned to all his previous activities six months after surgery. To our knowledge, this is the first reported case of a radial shaft psudoarthrosis treated with the Sauve'-Kapandji technique.
Collapse
Affiliation(s)
- E Theodorakis
- Department of Orthopedics and Traumatology, University Hospital Policlinico Umberto I, University Sapienza, Rome, Italy
| | | | | | | |
Collapse
|
27
|
Andrade W, Soares F, Lima E, Maciel M, Toledo C, Iyeyasu H, Cruz M, Fanelli M. Abstract P4-02-03: FDG PET/CT for early monitoring of response to neoadjuvant chemotherapy in breast cancer patients. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Neoadjuvant chemotherapy (NAC), initially used only for locally advanced breast cancer, is now commonly used in patients with operable but large breast cancer or unfavorable tumor/breast size index because increases the chances of performing breast conservative surgery (BCS) instead of mastectomy in this group of patients.
Patients and Methods: This is a prospective unicenter trial. FDG PET/CT were performed in 40 patients at baseline and after the second cycle of NAC. The level and relative changes in standardized uptake value (SUV) of FDG uptake were assessed regarding their ability to predict histopathologic response.
Pathologic complete response (pCR) was defined as no malignant cells (no invasive ductal carcinoma and no ductal carcinoma in situ) identifiable in sections from the site of the tumor in the breast and in the axillary lymph node.
Results: This prospectively study analyzed forty patients undergoing NAC, all female, age ranged 27–64 years (mean 41.0 years and median 38 years), all tumors were invasive ductal carcinoma, histological tumor grade 1, 2 and 3 were present respectively at 5%, 38.5% and 100% of the sample and nuclear grade 2 and 3 were present respectively at 12.5% and 87.5%. Estrogen receptor was positive in 60% of patients and the progesterone receptor was positive in 47.5% of patients. Her 2 was overexpressed in 12 patients (30%). Phenotype in this sample had the following distribution: 12.5% luminal A (5 patients), 50% Luminal B (20 patients: 14 patients with Ki-67> 14% and 6 cases with HER 2 overexpression), 15 % HER 2 (6 patients) and cases triple negative 9 (22.5%). size of the primary tumor ranged from 4.10 cm to 12.0 cm (mean 7.10 cm). The size of the primary tumor ranged from had a mean of 6.7 cm and a median of 6.0 cm. This group showed great uniformity in relation to primary chemotherapy. NAC with cyclophosphamide and adriamycin were administered to 38 patients. In this study, pCR was obtained in 12 patients (30%). Baseline FDG SUV referring to pCR group was 11.26 and 7.26 in non-pCR group (p = 0.04). FDG SUV after second cycle was 2.73 in pCR group and 4.64 in non-pCR group (p = 0.048). When analyzing ΔSUV (difference between baseline SUV and SUV after second cycle), pCR group had a mean reduction of 81.58% and non-pCR group had a mean reduction of 81.58% (p = 0.001). Receiver operating curve analyses were performed to deter mine optimal differentiation cut-off values of ΔSUV for differentiation of pCR and non-pCR. After two courses of NAC the optimal cutoff value to early differentiation between pCR from non-pCR were 59,1% in decrease of SUV. The sensitivity and specificity were 64,3% and 100,0%, respectively.
Conclusion: The optimum role of FDG PET in predicting the response of breast cancers to neoadjuvant chemotherapy is still not clearly defined and the SUV cut-off needs to be validated. FDG-PET allows for prediction of treatment response by the level of FDG uptake in terms of SUV at baseline and after two cycles of chemotherapy and FDG-PET may be helpful for individual treatment stratification in breast cancer patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-02-03.
Collapse
Affiliation(s)
- W Andrade
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| | - F Soares
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| | - E Lima
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| | - MdS Maciel
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| | - C Toledo
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| | - H Iyeyasu
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| | - M Cruz
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| | - M Fanelli
- A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil
| |
Collapse
|
28
|
Biason P, Hattinger C, Michelacci F, Fanelli M, Tavanti E, Sero V, Vella S, Serra M, Toffoli G. 1063 Loss of Heterozygosity (LOH) of Single Nucleotide Polymorphisms in DNA Repair Genes Associated With Cisplatin Resistance in Osteosarcoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71673-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
29
|
Rippo M, Villanova F, Ardori FT, Graciotti L, Amatori S, Manzotti S, Fanelli M, Gigante A, Procopio A. Dexamethasone Affects FAS-and Serum Deprivation-Induced Cell Death of Human Osteoblastic Cells through Survivin Regulation. Int J Immunopathol Pharmacol 2010; 23:1153-65. [DOI: 10.1177/039463201002300419] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Glucocorticoid-induced bone loss is the most prevalent form of secondary osteoporosis. Such loss could be due to the alteration of osteoclast and osteoblast lifespan through regulated apoptosis. The current study investigated the effect of dexamethasone on Fas- and starvation-induced apoptosis of mature osteoblasts and their precursors. Using the human osteoblastic hFOB1.19 and the MG63 osteosarcoma cell lines, we found that sub-lethal doses of dexamethasone act on pre-osteoblasts but not on mature cells by increasing their susceptibility to apoptosis. Apoptosis occurs in a caspase-dependent manner as both DNA fragmentation and mitochondrial transmembrane potential dissipation (ΔΨm) are inhibited by the pan-caspase inhibitor zVAD. The increased susceptibility of osteoblast precursors to apoptosis could be due to dexamethasone-mediated down-regulation of survivin expression. Dexamethasone can up-regulate survivin, and to a lesser extent Bcl-2, in mature cells but not in pre-osteoblasts. In addition, it can induce FLIP over-expression in osteosarcoma cells. All these effects are inhibited by the glucocorticoid antagonist RU486, indicating that dexamethasone action is specific and, furthermore, that it depends on glucocorticoid receptor. Finally, we have found that survivin and Bcl-2 are essential for pre- and mature osteoblast survival as their silencing is sufficient to induce spontaneous apoptosis in both cell types. In conclusion, our data outline a new molecular mechanism of glucocorticoid-mediated bone loss due to the enhanced apoptosis of precursors compared to mature osteoblasts. Furthermore, the data suggest a mechanism of dexamethasone-induced resistance of osteosarcoma cells to Fas- and stress-induced apoptosis.
Collapse
Affiliation(s)
- M.R. Rippo
- Laboratory of Experimental Pathology, Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
- Center of Clinical Pathology and Innovative Therapies, Italian National Research Center on Aging (INRCA, IRCCS), Ancona
| | - F. Villanova
- Laboratory of Experimental Pathology, Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
- Present address: St John's Institute of Dermatology, Biomedical Research Centre, King's College London, UK
| | - F. Tomassoni Ardori
- Laboratory of Experimental Pathology, Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
| | - L. Graciotti
- Laboratory of Experimental Pathology, Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
| | - S. Amatori
- Molecular Pathology and Oncology Laboratory “M. Paola”, Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Fano, Italy
| | - S. Manzotti
- Laboratory of Orthopedic Clinic, Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
| | - M. Fanelli
- Molecular Pathology and Oncology Laboratory “M. Paola”, Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Fano, Italy
| | - A. Gigante
- Laboratory of Orthopedic Clinic, Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
| | - A. Procopio
- Laboratory of Experimental Pathology, Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona
- Center of Clinical Pathology and Innovative Therapies, Italian National Research Center on Aging (INRCA, IRCCS), Ancona
| |
Collapse
|
30
|
Amatori S, Bagaloni I, Macedi E, Formica M, Giorgi L, Fusi V, Fanelli M. Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumour cells and induction of complex DNA structural alterations. Br J Cancer 2010; 103:239-48. [PMID: 20571494 PMCID: PMC2906739 DOI: 10.1038/sj.bjc.6605745] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Hydroxypyrones represent several classes of molecules known for their high synthetic versatility. This family of molecules shows several interesting pharmaceutical activities and is considered as a promising source of new antineoplastic compounds. METHODS In the quest to identify new potential anticancer agents, a new maltol (3-hydroxy-2-methyl-4-pyrone)-derived molecule, named malten (N,N'-bis((3-hydroxy-4-pyron-2-yl)methyl)-N,N'-dimethylethylendiamine), has been synthesised and analysed at both biological and molecular levels for its antiproliferative activity in eight tumour cell lines. RESULTS Malten exposure led to a dose-dependent reduction in cell survival in all the neoplastic models studied. Sublethal concentrations of malten induce profound cell cycle changes, particularly affecting the S and/or G2-M phases, whereas exposure to lethal doses causes the induction of programmed cell death. The molecular response to malten was also investigated in JURKAT and U937 cells. It showed the modulation of genes having key roles in cell cycle progression and apoptosis. Finally, as part of the effort to clarify the action mechanism, we showed that malten is able to impair DNA electrophoretic mobility and drastically reduce both PCR amplificability and fragmentation susceptibility of DNA. CONCLUSION Taken together, these results show that malten may exert its antiproliferative activity through the induction of complex DNA structural modifications. This evidence, together with the high synthetic versatility of maltol-derived compounds, makes malten an interesting molecular scaffold for the future design of new potential anticancer agents.
Collapse
Affiliation(s)
- S Amatori
- Molecular Pathology and Oncology Lab. 'PaoLa', Department of Biomolecular Sciences, University of Urbino 'Carlo Bo', via Arco d'Augusto, 2, 61032 Fano (PU), Italy
| | | | | | | | | | | | | |
Collapse
|
31
|
Baldassarre ME, Laneve A, Fanelli M, Russo F, Varsalone F, Sportelli F, Falcone MR, Laforgia N. Duration of meconium passage in preterm and term infants. Arch Dis Child Fetal Neonatal Ed 2010; 95:F74-5. [PMID: 20019200 DOI: 10.1136/adc.2009.159442] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippo MR, Procopio A, Pelicci PG, Catalano A, Fanelli M. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 2009; 66:184-90. [PMID: 19233506 DOI: 10.1016/j.lungcan.2009.01.015] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2008] [Revised: 10/21/2008] [Accepted: 01/19/2009] [Indexed: 01/12/2023]
Abstract
Malignant pleural mesothelioma (MPM) is a locally aggressive neoplasm, principally linked to asbestos fibres exposure. Strong evidences associate this pollutant with induction of DNA breaks, aberrant chromosomes segregation and important chromosomal rearrangements, considered crucial events in malignant transformation. A considerable contribution to cellular transformation in MPM is also given by the presence of high genomic instability, as well as by the increased DNA methylation, and consequent decreased expression, of tumor-suppressor genes. In this study we first demonstrated that MPM cells are characterized by a decreased methylation level of pericentromeric DNA sequences which can justify, at least in part, the genomic instability observed in this neoplasia. Concomitantly, we found a paradoxical increased expression of DNMT1, the most expressed DNA methyltransferases in MPM cells, DNMT3a and all five isoforms of DNMT3b. Thus, we compared two experimental strategies, DNMT1 silencing and usage of a demethylating agent (5-aza-2'-deoxycytidine or Decitabine), both theoretically able to revert the locally hypermethylated phenotype and considered potential future therapeutic approaches for MPM. Interestingly, both strategies substantially decrease cell survival of MPM cells but the antitumor activity of Decitabine, differently from DNMT1 silencing, is mediated, at least in part, by a p53-independent p21 upregulation, and is characterized by the arrest of MPM cells at the G2/M phase of the cell cycle. These results indicate that the two approaches act probably through different mechanisms and, thus, that DNMT1 silencing can be considered an effective alternative to Decitabine for cancer treatment.
Collapse
Affiliation(s)
- S Amatori
- Molecular Pathology and Oncology Lab. M.Paola, Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61032 Fano, PU, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Valle G, Stanislao M, Gimelli A, Vigna C, Facciorusso A, Fanelli M, Marzullo P. Prediction of response and prognosis after cardiac resynchronisation therapy. Heart 2008; 94:1496; author reply 1496. [PMID: 18931160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
|
34
|
Khaleque MA, Bharti A, Gong J, Gray PJ, Sachdev V, Ciocca DR, Stati A, Fanelli M, Calderwood SK. Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene 2008; 27:1886-93. [PMID: 17922035 DOI: 10.1038/sj.onc.1210834] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2006] [Revised: 08/16/2007] [Accepted: 09/01/2007] [Indexed: 11/08/2022]
Abstract
Heat shock factor 1 (HSF1), the transcriptional activator of the heat shock genes, is increasingly implicated in cancer. We have shown that HSF1 binds to the corepressor metastasis-associated protein 1 (MTA1) in vitro and in human breast carcinoma samples. HSF1-MTA1 complex formation was strongly induced by the transforming ligand heregulin and complexes incorporated a number of additional proteins including histone deacetylases (HDAC1 and 2) and Mi2alpha, all components of the NuRD corepressor complex. These complexes were induced to assemble on the chromatin of MCF7 breast carcinoma cells and associated with the promoters of estrogen-responsive genes. Such HSF1 complexes participate in repression of estrogen-dependent transcription in breast carcinoma cells treated with heregulin and this effect was inhibited by MTA1 knockdown. Repression of estrogen-dependent transcription may contribute to the role of HSF1 in cancer.
Collapse
Affiliation(s)
- M A Khaleque
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 2215, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Reale L, Kaiser J, Reale A, Lai A, Flora F, Balerna A, Cinque G, Fanelli M, Ruggieri F, Faenov A, Pikuz T, Tucci A, Poma A, Zuppella P, Liska M, Malina R. Mapping the intake of different elements in vegetal tissues by dual-energy X-ray imaging at DaPhine synchrotron light source. Microsc Res Tech 2008; 71:179-85. [PMID: 17992692 DOI: 10.1002/jemt.20538] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This article reports on the first utilization of the soft X-ray beamline at the DaPhine synchrotron light source for mapping the intake of different elements in plant tissues. As a test, the method of dual-energy X-ray microradiography was applied to the investigation of the natural sulfur content in dried leaf and root samples. Our ultimate goal was to monitor the pollutant lead and its intake, which was added in controlled doses to the hydroponic medium of laboratory-controlled samples of vegetal species. The results obtained by the nondestructive X-ray radiographic analysis are compared to the values of concentrations determined by a standard chemical analysis utilizing atomic absorption spectroscopy. From this comparison the validity of the X-ray detection of heavy metals in biological samples has been confirmed. The superposition of the dual energy results on the simple planar radiography shows the representation of the pollutant intake directly on the sample structures. It should be pointed out that this method, developed here for plant root and leaves could be applied to any biological sample of interest, but the preparation and observation conditions necessitate different strategies according to the type of sample under analysis.
Collapse
Affiliation(s)
- L Reale
- Faculty of Sciences, University of L'Aquila, gc LNGS INFN, INFM 67010 Coppito, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, Amatori S, Andreoni F, Magnani M, De Maria R, Santoni A, Minucci S, Pelicci PG. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 2007; 27:358-65. [PMID: 17653095 DOI: 10.1038/sj.onc.1210642] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Cancer is generally characterized by loss of CG dinucleotides methylation resulting in a global hypomethylation and the consequent genomic instability. The major contribution to the general decreased methylation levels seems to be due to demethylation of heterochromatin repetitive DNA sequences. In human immunodeficiency, centromeric instability and facial anomalies syndrome, demethylation of pericentromeric satellite 2 DNA sequences has been correlated to functional mutations of the de novo DNA methyltransferase 3b (DNMT3b), but the mechanism responsible for the hypomethylated status in tumors is poorly known. Here, we report that human glioblastoma is affected by strong hypomethylation of satellite 2 pericentromeric sequences that involves the stem cell compartment. Concomitantly with the integrity of the DNMTs coding sequences, we report aberrations in DNA methyltrasferases expression showing upregulation of the DNA methyltransferase 1 (DNMT1) and downregulation of the de novo DNA methyltransferase 3a (DNMT3a). Moreover, we show that DNMT3a is the major de novo methyltransferase expressed in normal neural progenitor cells (NPCs) and its forced re-expression is sufficient to partially recover the methylation levels of satellite 2 repeats in glioblastoma cell lines. Thus, we speculate that DNMT3a decreased expression may be involved in the early post-natal inheritance of an epigenetically altered NPC population that could be responsible for glioblastoma development later in adult life.
Collapse
Affiliation(s)
- M Fanelli
- Centre of Biotechnology, University of Urbino, Fano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Fanelli M, Arora R, Glass A, Litt R, Qiu D, Silva L, Tonkovich AL, Weidert D. Micro-scale distillation—I: simulation. ACTA ACUST UNITED AC 2007. [DOI: 10.2495/mpf070201] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
38
|
Baldassarre ME, Altomare MA, Fanelli M, Carbone D, Di Bitonto G, Mautone A, Laforgia N. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr Metab Immune Disord Drug Targets 2007; 7:1-5. [PMID: 17346198 DOI: 10.2174/187153007780059441] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Calprotectin, a protein composed by two subunits of 8 and 14 kD respectively, is released by neutrophils in the biological fluids under inflammatory states. For instance, detection of calprotectin in faeces represents a diagnostic tool in the case of inflammatory bowel disease. Quite interestingly, calprotectin is increased in the stool of healthy newborns from day three up to day thirty and, physiologically, this increase may be interpreted as a defense mechanism against yeast and fungi. Therapeutic attempts at inhibiting the deleterious effect of calprotectin have been experimentally made by using lycoricinidol. This natural compound is able to hamper the calprotectin-induced apoptosis on the one hand. On the other hand, the same compound plays a prophylactic role in the course of experimental arthritis in rats.
Collapse
Affiliation(s)
- M E Baldassarre
- Unità Operativa di Neonatologia e Terapia Intensiva Neonatale, Università degli Studi di Bari, Bari, Italia.
| | | | | | | | | | | | | |
Collapse
|
39
|
D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women. Panminerva Med 2006; 48:215-21. [PMID: 17215793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
AIM Osteoporosis is a bone disease, characterized by a reduction of bone resistance; in postmenopausal period bone metabolism is imbalanced. Several parameters have been proposed as markers of bone metabolism; the attention have been recently placed on the receptor of activator of NF(Kappa)B ligand receptor (RANKL) and osteoprotegerin (OPG), namely RANKL/OPG system. The aim of this paper is to evaluate changes in postmenopausal women in serum concentration of OPG, RANKL, and their ratio (i.e. RANKL/OPG ratio), osteopontin (OPN), bone-type alcaline phosphatase (BAP), serum-N-Telopeptide of type I collagen (serum-NTX); and their correlations with bone mineral density (BMD). METHODS An Apulian population group of 163 native postmenopausal women were followed at the Osteoporosis Centre of Policlinico of Bari (Southenrn Italy). Patients were classified into 3 separate groups, according to T-score: osteoporotic, osteopenic and control group. Serum concentrations of OPG, RANKL, RANKL/OPG ratio, BAP and NTX have been calculated. RESULTS No differences were found in OPG and BAP values. Significant correlations were found in the osteopenic group between OPG and RANKL (negative), and between RANKL and OPN or serum-NTX, OPN and serum-NTX or RANKL/OPG ratio, BAP and serum-NTX, serum-NTX and RANKL/OPG ratio (positive). In the other groups a significant correlation was observed between BAP and NTX. CONCLUSIONS In postmenopausal women, important modifications of bone metabolism markers (i.e. RANKL, OPG and OPN) could be due to serious engagement of bone turnover, especially in the pre-osteoporotic phase. Low bone density in postmenopausal women should be identified as soon as possible, and urgent measures are needed to reverse the process. Parameters namely RANKL e OPG may become an important index for the evaluation of the activity of drugs against osteoporosis, old and new like AMG 162 (anti-RANKL action).
Collapse
Affiliation(s)
- M D'Amore
- Unit of Rheumatology, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy.
| | | | | | | | | |
Collapse
|
40
|
Ambrogini P, Minelli A, Lattanzi D, Ciuffoli S, Fanelli M, Cuppini R. Synaptically-silent immature neurons show gaba and glutamate receptor-mediated currents in adult rat dentate gyrus. Arch Ital Biol 2006; 144:115-26. [PMID: 16642790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
The fate of adult-generated neurons in dentate gyrus is mainly determined early, before they receive synapses. In developing brain, classical neurotransmitters such as GABA and glutamate exert trophic effects before synaptogenesis. In order for this to occur in adult brain as well, immature non-contacted cells must express functional receptors to GABA and glutamate. In this investigation, patch-clamp recordings were used in adult rat dentate gyrus slices to assess the presence and analyze the characteristics of GABA- and glutamate-evoked currents in highly immature, synaptically-silent granule cells. Whole-cell patch-clamp recordings showed that all the analyzed cells responded to puff application of GABA and most of them responded to glutamate. Currents evoked by GABA were mediated exclusively by GABAA receptors and those elicited by glutamate were mediated by NMDA and AMPA/Kainate receptors. GABAA receptor-mediated currents were reduced by furosemide, which suggests that synaptically-silent immature neurons express high-affinity, alpha4-subunit-containing GABAA receptors. Gramicidin-perforated-patch recordings showed that GABAA receptor-mediated currents exerted a depolarizing effect due to high intracellular chloride concentration. Synaptically-silent immature cells shared morphological and electrophysiological properties with GFP-expressing, 7-day-old adult-generated granule layer cells, indicating that they could be in the first week of life, the period of maximal newborn cell death. Moreover, the presence of functional GABA and glutamate receptors was confirmed in these GFP-expressing cells. Present findings are mostly consistent with previous data obtained in female mice undergoing spontaneous activity and in transgenic mice, except for some inconsistencies about the presence of functional glutamatergic receptors. We speculate that adult-generated, non-contacted granule cells may be able to sense activity-related variations of GABA and glutamate extracellular levels. This condition is necessary, even if not sufficient, for these neurotransmitters to have a direct role in addressing cell survival.
Collapse
Affiliation(s)
- P Ambrogini
- Istituto di Scienze Fisiologiche, Centro di Biotecnologie, Università di Urbino Carlo Bo, Italy.
| | | | | | | | | | | |
Collapse
|
41
|
Sentinelli F, Filippi E, Cavallo MG, Romeo S, Fanelli M, Baroni MG. The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPARgamma agonist restores normal cell signaling and differentiation. J Endocrinol 2006; 188:271-85. [PMID: 16461553 DOI: 10.1677/joe.1.06290] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The insulin receptor substrate-1 (IRS-1) plays a central role in insulin sensitivity, and association studies have shown that the IRS-1 G972R variant is a risk factor for insulin resistance. However, how this mutation may lead to impaired insulin sensitivity is still to be determined. Our study aimed to evaluate, after transfection of the IRS-1 G972R variant in 3T3L1 adipocytes, the effect of this mutation on insulin signaling and on cell differentiation. The 3T3L1 cells were transfected with pcDNA3 expression vector containing either the human wild-type IRS-1 or the G972R variant. After induction of differentiation, the 3T3L1 transfected with wild-type IRS-1 differentiated in 6-8 days, while the cells transfected with G972R variant did not differentiate. To determine whether the defect in IRS-1 was responsible for this, we analyzed the expression of several genes involved in the insulin signaling pathway. Results showed that PPARgamma expression was significantly reduced in cells transfected with the mutated IRS-1, together with a significant decrease in binding of phosphatidylinositol-3 kinase (PI 3-kinase) to IRS-1 G972R and in PI 3-kinase activity. In addition, we observed that the interaction between the insulin receptor (IR) and the IRS-1 G972R protein was increased and that the autophosphorylation of the IR was significantly inhibited in 3T3L1-G972R cells compared with 3T3L1-WT. Treatment of the 3T3L1-G972R cells with pioglitazone (PIO), a PPARgamma agonist, restored differentiation with higher level of PPARgamma expression and restoration of PI 3-kinase binding to IRS-1 G972R and PI 3-kinase activity. IR autophosphorylation was also increased. Withdrawal of PIO in fully differentiated 3T3L1-G972R cells determined the reappearance of the insulin signaling defect. Finally, we observed higher levels of IRS-2 expression, suggesting that IRS-2 may play a more important role in adipocyte insulin signaling. In conclusion, IRS-1 G972R variant impairs insulin signaling, and treatment with PPARgamma agonist restores the normal phenotype of 3T3L1 cells.
Collapse
Affiliation(s)
- F Sentinelli
- Department of Clinical Sciences, Division of Endocrinology, Policlinico Umberto I, University of Rome 'La Sapienza', Viale del Policlinico 155, 00161 Rome, Italy
| | | | | | | | | | | |
Collapse
|
42
|
D'Amore M, Minenna G, Fanelli M, D'Amore S, Favoino B. Bone density and HLA antigens in patients with progressive systemic sclerosis. Minerva Med 2005; 96:61-2. [PMID: 15827542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
|
43
|
Baroni MG, Leonetti F, Sentinelli F, Romeo S, Filippi E, Fanelli M, Ribaudo MC, Zappaterreno A, Fallarino M, Di Mario U. The G972R variant of the insulin receptor substrate-1 (IRS-1) gene is associated with insulin resistance in "uncomplicated" obese subjects evaluated by hyperinsulinemic-euglycemic clamp. J Endocrinol Invest 2004; 27:754-9. [PMID: 15636429 DOI: 10.1007/bf03347518] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Several association studies have indicated the insulin receptor substrate-1 (IRS-1) gene G972R variant as a genetic risk factor for insulin resistance, particularly in presence of obesity. A few studies have also suggested a possible effect of the G972R variant on insulin secretion. The aim of this study was to evaluate the role of the IRS-1 gene G972R variant in 61 subjects with "uncomplicated" obesity [i.e. without diabetes, hypertension, dyslipidemia, coronary artery disease (CAD)], studied by hyperinsulinemic-euglycemic clamp. The presence of the G972R variant, detected in real-time with LightCycler hybridisation probes, was related to the indexes of insulin sensitivity. Furthermore, the possible role of this variant on insulin secretion was studied by means of insulin release indexes derived from oral tolerance test (OGTT). Twenty-four point five percent (24.5%) (no.=15) of the obese subjects proved to be carriers of the G972R variant. M index (p<0.05), non-oxidative glucose (p<0.01), insulin clearance (p<0.03) and insulin sensitivity index (ISI) (p<0.005) were all significantly reduced in G972R carriers compared to non-carriers, indicating a significant reduction in insulin sensitivity in carriers of the variant. A logistic regression analysis confirmed the independent association between the G972R variant and reduced insulin sensitivity (p<0.03). The interaction between obesity and the G972R variant was also independently associated with a reduced insulin sensitivity (p<0.005), suggesting that obesity and G972R variant were more than additive in predicting insulin resistance. The analysis of insulin release indexes did not show any significant differences. Our results demonstrate the association of the G972R variant of the IRS-1 gene with reduced insulin sensitivity in obese subjects, and indicate a possible interaction between the IRS-1 variant and obesity in worsening of insulin sensitivity.
Collapse
Affiliation(s)
- M G Baroni
- Department of Clinical Sciences, Division of Endocrinology, University of Rome "La Sapienza", Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Saracino A, Morrone LF, Suriano V, Niccoli-Asabella A, Ramunni A, Fanelli M, Rubini G, Coratelli P. A simple method for correcting overestimated glomerular filtration rate in obese subjects evaluated by the Cockcroft and Gault formula: a comparison with 51Cr EDTA clearance. Clin Nephrol 2004; 62:97-103. [PMID: 15356966 DOI: 10.5414/cnp62097] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
AIM The Cockcroft and Gault formula is a quick and reliable method for calculating creatinine clearance without a 24-hour urine collection (CG-cl). In obese subjects an excess of fat mass provokes a reduction in daily creatinine urine excretion per body kilo weight and is responsible for overestimated renal function when calculated by CG-cl. The aim of this study was to devise a simple correction method which could also make use of CG-cl in obese subjects. PATIENTS AND METHODS In 52 subjects with a body mass index (BMI) > 25, renal function was assessed by simultaneously determining creatinine clearance using 24-hour urine collection (Cr-cl) and the CG-cl. The percentage difference between the 2 clearances (delta %) was correlated with BMI for each patient using simple linear regression analysis. The estimated regression model (delta% = 1.217 BMI-- 24.81) provided the following CG-cl correction formula for obese subjects: Corrected CG-cl = CG-cl (1.25 - 0.012 BMI). Its validity was evaluated in another group of 20 subjects with BMI > 25 by comparing the results obtained with Corrected CG-cl to those obtained by CG-cl and MDRD formula (MDRD-cl) using the clearance of 51Cr-EDTA (5 Cr-EDTA-cl) as the GFR measurement gold standard. RESULTS AND CONCLUSION Linear regression analysis of CG-cl, MDRD-cl and Corrected CG-cl compared to 5tCr-EDTA-cl (considered as the independent variable) resulted in the following determination coefficients (R2): 0.687; 0.818; 0.947, respectively. In conclusion, this formula can be considered a quick and reliable method for CG-cl correction in obese subjects.
Collapse
Affiliation(s)
- A Saracino
- Nephrology and 2Nuclear Medicine Units, Department of Internal and Public Medicine, University of Bari, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Morabito A, Carillio G, Bonginelli P, Amici S, Longo R, Sarmiento R, Fanelli M, Stani SC, Gattuso D, Gasparini G. Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Morabito
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - G. Carillio
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - P. Bonginelli
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - S. Amici
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - R. Longo
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - R. Sarmiento
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - M. Fanelli
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - S. C. Stani
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - D. Gattuso
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - G. Gasparini
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| |
Collapse
|
46
|
Gasparini G, Gattuso D, Morabito A, Carillio G, Vitale S, Fanelli M, Torino F, Bonginelli P, Castellana MA, De Sio L. Rofecoxib associated with weekly irinotecan and infusional 5-fluorouracil as second-line treatment for metastatic colorectal cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3686] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Gasparini
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - D. Gattuso
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - A. Morabito
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - G. Carillio
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - S. Vitale
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - M. Fanelli
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - F. Torino
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | - P. Bonginelli
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| | | | - L. De Sio
- San Filippo Neri Hospital, Division of Oncology, Rome, Italy
| |
Collapse
|
47
|
Abstract
Physiological angiogenesis occurs during embryogenesis, wound healing and reproductive functions in adults. Abnormal angiogenesis takes place in certain chronic diseases (diabetes, psoriasis, rheumatoid arthritis, etc.) and tumours. Genetic changes and local stresses including hypoxia, glucose deprivation and oxidative stress play a pivotal role in angiogenesis switch, which is necessary for tumour development and is rate-limiting for tumour progression. Angiogenesis is tightly regulated by pro- and anti-angiogenic growth factors with a series of complex and interrelated steps. Activated endothelial cells (ECs) migrate as a solid cord and, subsequently, form lumina; the sprout tips then anastomose to form vessel loops or networks. One of the final events is the laying down of a basement membrane and the structural support of pericytes. The molecular alterations that sustain angiogenesis represent novel targets for rationally designed anti-cancer treatment strategies. Inhibition of angiogenesis presents certain advantages on conventional therapies, such as the direct accessibility from the circulation, and the potential low rate of drug resistance related to the genetic stability of ECs. Certain anti-angiogenic compounds were found to have potent anticancer property in in vivo experimental studies. Nevertheless, in contrast to preclinical studies, the first generation of anti-angiogenic drugs tested in clinical trials have shown a moderate activity in advanced disease partly due to suboptimal schedules of therapy or biases in study design.
Collapse
Affiliation(s)
- R Longo
- Division of Medical Oncology, Azienda Complesso Ospedaliero, 'San Filippo Neri', Rome, Italy
| | | | | | | | | | | |
Collapse
|
48
|
Palmeri S, Leonardi V, Tamburo De Bella M, Morabito A, Vaglica M, Accurso V, Ferraù F, Failla G, Agostara B, Massidda B, Valenza R, Fanelli M, Gasparini G. Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. Oncology 2002; 63:205-12. [PMID: 12381898 DOI: 10.1159/000065466] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE We conducted a multi-institutional phase II study to evaluate the tolerability and activity of a sequential schedule of treatment with doxorubicin and docetaxel in chemotherapy-naive women with advanced breast cancer. METHODS A total of 73 patients with PS (ECOG) 0-2, aged <70 years and adequate bone marrow, renal, liver and cardiac functions were included in the study (13 stage III B and 60 stage IV). The schedule of administration was doxorubicin 50 mg/m2 by intravenous (i.v.) 30 min injection on day 1 followed the day after by docetaxel 75 mg/m2, by i.v. 60 min infusion. Cycles were repeated every 28 days. RESULTS Overall, the median number of administered cycles was 6 (range 1-14). The most common toxicity was hematological, with 56.2% of the patients who experienced grade 3-4 neutropenia. However, febrile neutropenia occurred only in 2.8% of the cases. The median cumulative dose of doxorubicin was 350 mg/m2 (range 50-700 mg/m2). Eleven patients (15.4%) were documented to have >10% but <20% decrease in the left ventricular ejection fraction. No case of congestive heart failure was recorded. No patient experienced treatment-related death. Among the 68 evaluable patients, the overall objective response rate was 73.5% (95% confidence limits: 63-84%): 10 patients (14.7%) obtained a complete remission and 40 (58.8%) had a partial response. Only 10 patients (14.7%) experienced progressive disease. The median duration of response was 10 months (2-54+). CONCLUSION This sequential treatment with doxorubicin and docetaxel is an effective, feasible and a well-tolerated regimen. The main toxicity was neutropenia. The lack of cardiotoxicity is an important advantage of such a doxorubicin-docetaxel combination and it justifies phase III comparative studies with other anthracyclines/taxanes containing schedules in both advanced and early-stage breast cancer.
Collapse
Affiliation(s)
- S Palmeri
- Istituto di Clinica Medica, Cattedra di Oncologia Medica, Università di Palermo, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Chiechi LM, Secreto G, D'Amore M, Fanelli M, Venturelli E, Cantatore F, Valerio T, Laselva G, Loizzi P. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. Maturitas 2002; 42:295-300. [PMID: 12191852 DOI: 10.1016/s0378-5122(02)00158-5] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
OBJECTIVES To compare the effect of a soy rich diet and hormone replacement therapy (HRT) on the main biomarkers of bone turnover and bone mineral density (BMD) at postmenopausal age. METHODS 187 healthy asymptomatic postmenopausal women, aged 39-60, were recruited and randomized into a soy rich diet group, a HRT group, and a control group. Bone biomarkers and BMD were evaluated at baseline and after 6 months at the end of the study. RESULTS Diet is not as effective as HRT in reducing the postmenopausal turnover; however diet stimulates bone osteoblastic activity, as evidenced by significant increase in osteocalcin concentrations. BMD decreases significantly only in the control group, but not in the intervention groups. CONCLUSIONS Our data suggest that soy products could be effective in reducing the risk of osteoporosis in asymptomatic postmenopausal women, but our findings should be confirmed before recommending the diet as a valid alternative to HRT.
Collapse
Affiliation(s)
- L M Chiechi
- Department of Obstetrics and Gynecology, University of Bari, Corso Alcide de Gasperi 495, 70125 Bari, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Orsini G, Laricchia L, Fanelli M. [Low-dose combination oral contraceptives use in women with uterine leiomyomas]. Minerva Ginecol 2002; 54:253-61. [PMID: 12063441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
BACKGROUND To evaluate the effects of the last generation of oral contraceptives (OC) on uterine leiomyomas. METHODS DESIGN non-randomized perspective study on the effects of the last generation of oral contraceptives on uterine myomas during 24 months follow-up. SETTING III Unit of Obstetrics and Gynecology, University of Bari. PARTICIPANTS between 1999 and 2000 a total of 121 asymptomatic women with only one subserous and/or intramural uterine myoma, having diameter pound 25 mm have been recruited. These patients were divided into two groups: the treatment group was composed of 53 women and was treated with last generation pill containing 20 microgram of ethynilestradiol and 150 microgram of desogestrel or 20 microgram of ethynilestradiol and 75 microgram of gestodene, while the control group was composed of 68 women having no hormonal therapy. In both groups the uterine myoma size (evaluated by transvaginal ultrasonography), the duration of menstrual flow and the hematocrit at the time of recruitment, after 12 months and after 24 months were examined. RESULTS Forty-eight (90.6%) women belonging to the study group completed 2 years of OC use; only sixty women (88.2%) belonging to the control group completed the study. The use of the last generation oral contraceptives for 2 years didn't increase significantly uterine myomas size; besides after 24 months there was a significant reduction of more than two days of menstrual flow, and a significant increase of two and a half points of hematocrit. On the contrary, in the control group, we found a significant increase of uterine myoma volume, a not significant increase of menses duration and a not significant reduction of hematocrit. CONCLUSIONS The prolonged use of the last generation of oral contraceptives does not affect the uterine myomas volume increase and furthermore it produces a significant reduction in the duration of menstrual flow with a significant increase in hematocrit.
Collapse
Affiliation(s)
- G Orsini
- III Unità Operativa di Ginecologia e Ostetricia, Cattedra di Fisiopatologia della Riproduzione Umana, Dipartimento di Scienze Chirurgiche, Università degli Studi, Bari, Italy.
| | | | | |
Collapse
|